Pharmacogenomics is the study of how an individual's genetic inheritance affects the body's response to drugs. Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to an individual's genetic makeup. Several studies have shown that both adverse and beneficial responses to cardiovascular drugs can be influenced by single nucleotide polymorphisms in genes coding for metabolising enzymes, drug transporters and drug targets. Despite the large amount of data about gene-drug interactions, the translation of pharmacogenomics in clinical practise is slow. To improve this, there is a need of new technology and large prospective trials allowing for simultaneous analysis of multiple genetic variants in molecular pathways that could affect drug disposition and action.

Mango, R., Vecchione, L., Raso, B., Borgiani, P., Brunetti, E., Mehta, J., et al. (2005). Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. EXPERT OPINION ON PHARMACOTHERAPY, 6(15), 2565-2576 [10.1517/14656566.6.15.2565].

Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy

VECCHIONE, LUCIA;RASO, BARBARA FRANCESCA MARIA CRISTI;BORGIANI, PAOLA;LAURO, RENATO;ROMEO, FRANCESCO;NOVELLI, GIUSEPPE
2005-12-01

Abstract

Pharmacogenomics is the study of how an individual's genetic inheritance affects the body's response to drugs. Pharmacogenomics holds the promise that drugs might one day be tailor-made for individuals and adapted to an individual's genetic makeup. Several studies have shown that both adverse and beneficial responses to cardiovascular drugs can be influenced by single nucleotide polymorphisms in genes coding for metabolising enzymes, drug transporters and drug targets. Despite the large amount of data about gene-drug interactions, the translation of pharmacogenomics in clinical practise is slow. To improve this, there is a need of new technology and large prospective trials allowing for simultaneous analysis of multiple genetic variants in molecular pathways that could affect drug disposition and action.
dic-2005
Pubblicato
Rilevanza internazionale
Articolo
Sì, ma tipo non specificato
Settore MED/03 - GENETICA MEDICA
English
Con Impact Factor ISI
Animals; Polymorphism, Single Nucleotide; Humans; Cardiovascular Diseases; Cardiovascular Agents; Pharmacogenetics
Mango, R., Vecchione, L., Raso, B., Borgiani, P., Brunetti, E., Mehta, J., et al. (2005). Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy. EXPERT OPINION ON PHARMACOTHERAPY, 6(15), 2565-2576 [10.1517/14656566.6.15.2565].
Mango, R; Vecchione, L; Raso, Bfmc; Borgiani, P; Brunetti, E; Mehta, J; Lauro, R; Romeo, F; Novelli, G
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/30261
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 10
social impact